Status:
UNKNOWN
Continuous Femoral Block With Levobupivacaine 0.125% or Ropivacaine 0.2% in Elderly Patients With Femoral Fractures
Lead Sponsor:
Hospital Municipal Miguel Couto
Conditions:
Femur Fracture
Hip Fractures
Eligibility:
All Genders
70+ years
Phase:
NA
Brief Summary
This study evaluates the continuous femoral block between levobupivacaine 0.125% and ropivacaine 0.2% in patients with proximal femoral fracture.These patients will be divided into 2 groups of 35 pati...
Detailed Description
Pain is associated with neurohormonal stress, myocardial ischemia and delayed mobilization, thus being able to increase the hospitalization time and associated with increased postoperative mortality. ...
Eligibility Criteria
Inclusion
- 70 years old or more
- patients with femur fracture
- physical status risk American Society of Anesthesiologists (ASA) P1 - P3
Exclusion
- physical status ASA P4
- patients with BMI \> 35
- systemic infection
- Injury or infection at the site of installation of the femoral perineural catheter
- Catheter displacement of the perineural site
- Montreal Cognitive Assessment (MoCA) \< 26
- Patients operated before 24 hours of hospital admission
Key Trial Info
Start Date :
August 28 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 8 2021
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT03815565
Start Date
August 28 2017
End Date
January 8 2021
Last Update
February 20 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rafael M Linhares
Rio de Janeiro, Brazil, 22776050